COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU) (RE-GENERATION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03207568
Recruitment Status : Completed
First Posted : July 5, 2017
Last Update Posted : July 5, 2017
Information provided by (Responsible Party):
Bolton Medical

Brief Summary:

The objective of the study is to evaluate the safety and performance of Relay Pro and Relay NBS Pro devices in humans having thoracic aortic pathologies.

Clinical results will be used to apply for the CE certification.

Condition or disease Intervention/treatment Phase
Aorta, Thoracic Pathologies Aortic Aneurysm, Thoracic Aortic Aneurysm Device: Thoracic Endovascular Aortic Repair (TEVAR) Not Applicable

Detailed Description:

This is a prospective, multicenter, non-randomized, single arm clinical study in patients presenting thoracic aortic pathologies. Patients with thoracic aortic pathologies who are planned to undergo thoracic endovascular aortic repair (TEVAR) with a stent-graft based on routine clinical assessments performed as part of the patients' standard care will be screened after obtaining the informed consent from the patients, and if eligible, enrolled and scheduled for the implantation procedure with the study device.

Following a baseline assessment, the implantation procedure will be performed according to the Instructions for Use and local routine practice. A follow-up visit will be performed 30 days after the implantation procedure. The investigator will perform assessments of the implantation procedure and device system and document adverse events and device deficiencies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Relay Pro and Relay NBS Pro device
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: RE-GENERATION: An EU Clinical Study to Evaluate the Safety and Performance of the Relay Pro and Relay Non Bare Stent (NBS) Pro Stent-graft Devices in Patients With Thoracic Aortic Pathologies
Actual Study Start Date : October 25, 2014
Actual Primary Completion Date : April 14, 2016
Actual Study Completion Date : April 30, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aneurysms

Arm Intervention/treatment
Experimental: Relay Pro Device
The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
Device: Thoracic Endovascular Aortic Repair (TEVAR)
thoracic endovascular repair (TEVAR) with a thoracic stent-graft
Other Names:

Primary Outcome Measures :
  1. Freedom from aneurysm or dissection-related mortality [ Time Frame: 30 days or less ]
    All deaths due to the treated pathology, including aneurysm rupture, complications of TEVAR leading to new aortic pathology (e.g., retrograde dissection leading to fatal cardiac tamponade).

  2. Delivery and deployment success evaluation [ Time Frame: 30 days or less ]

    Success will be based on the Delivery system evaluation, overall rate of vascular access complications

    • Rate of access failures
    • Rate of deployment system difficulties

    will be analyzed descriptively.

Secondary Outcome Measures :
  1. Major device-related adverse events (MAE) [ Time Frame: 30 days after the procedure ]

    MAEs include:

    • Endoleak (types I, Ill and IV)
    • Stent migration (>10 mm)2
    • Lumen occlusion
    • Aorta rupture
    • Conversion to open repair

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient diagnosed with thoracic aorta pathology (aneurysm, pseudoaneurysm, dissection, penetrating ulcer or intramural hematoma) suitable for TEVAR with a Relay Pro or Relay NBS Pro stent-graft; diagnosis must be confirmed by contrast computed tomography angiography (CTA) or magnetic resonance imaging (MRI) within 3 months of the planned implant procedure.
  • Proximal and distal aortic necks suitable for stent-graft placement (i.e., diameter ranging between 18 and 42 mm)
  • Proximal and distal landing zones suitable for the stent-graft
  • Adequate vascular access for insertion of the delivery system, i.e., femoral or iliac arteries a minimum 6 mm in diameter to accommodate the 19 to 22-Fr outer-diameter delivery system and no excessive disease precluding delivery system entry/passage or iliac arteries that could be extended via an access conduit.
  • Written informed consent provided by the subject him/herself (not a representative) upon enrollment

Exclusion Criteria:

Patients who meet one or more of the following criteria are not eligible:

  • Aneurysm/lesion location not accessible to the delivery system and stent placement
  • Arterial access size insufficient for delivery system entrance or impossibility to perform a surgical access conduit
  • Treatment of lesion that would require a delivery system with usable length greater than 90 cm
  • Excessive arterial disease precluding delivery system entrance or passage
  • Systemic infection
  • Arterial tortuosity not allowing passage of the delivery system
  • Arterial or aneurysm/lesion size incompatible with stent graft
  • Has congenital connective tissue disease rendering the aneurysm/lesion untreatable
  • Mycotic aneurysm/lesions
  • Aortic inner diameter that cannot accommodate the expanded Inner Secondary Sheath outer diameter of approximately 10mm
  • Native bleeding diathesis
  • Any condition (medical or anatomic) which makes the patient not suitable for endovascular
  • repair according to the opinion of the investigator
  • Untreatable allergy or history of allergic reaction to radiographic contrast medium
  • Untreatable allergy or history of allergic reaction to anticoagulants
  • Hypersensitivity to polyester or nitinol or any of the components of the Relay device
  • Patient underwent prior thoracic aortic repair (endovascular or surgical)
  • Participation in an investigational clinical study involving a new chemical entity or medical device within 3 months or 1 year, respectively, prior to the planned procedure
  • Patient not willing to give consent for transmission of personal "pseudonymised" data
  • For females: pregnancy or lactation
  • Women of childbearing potential (not postmenopausal or surgically sterile) not willing to use an effective method of contraception during the study. Effective methods are hormonal contraceptives (e.g., oral, implanted, or injected), intrauterine device (IUDs), and sexual abstinence.
  • Patient committed to an institution by virtue of an order issued either by the courts or by an authority
  • Patient who is unable to comply with the requirements of the study or who in the opinion of theinvestigator should not participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03207568

Sponsors and Collaborators
Bolton Medical
Layout table for investigator information
Principal Investigator: Vicenç Riambau Thorax Institute Hospital Clínic de Barcelona
Layout table for additonal information
Responsible Party: Bolton Medical Identifier: NCT03207568    
Other Study ID Numbers: IP-0011-14
First Posted: July 5, 2017    Key Record Dates
Last Update Posted: July 5, 2017
Last Verified: June 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Aneurysm, Dissecting
Aortic Aneurysm
Aortic Aneurysm, Thoracic
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases